emerg
associ
coronaviru
diseas
covid
imper
need
diagnost
test
identifi
infect
although
nucleic
acid
test
nat
consid
gold
standard
serolog
test
base
antibodi
could
help
howev
individu
studi
measur
accuraci
variou
test
usual
underpow
inconsist
thu
comparison
differ
test
need
perform
systemat
review
metaanalysi
follow
prisma
guidelin
conduct
literatur
search
pubm
medrxiv
biorxiv
statist
analysi
use
bivari
method
metaanalysi
diagnost
test
pool
sensit
specif
evalu
igm
igg
test
base
enzymelink
immunosorb
assay
elisa
chemiluminesc
enzym
immunoassay
clia
fluoresc
immunoassay
fia
pointofcar
poc
later
flow
immunoassay
lfia
base
immunochromatographi
total
identifi
elig
studi
includ
data
individu
analys
show
test
use
antigen
sensit
n
antigenbas
test
igg
test
perform
better
compar
igm
one
show
better
sensit
sampl
taken
longer
onset
symptom
moreov
irrespect
method
combin
iggigm
test
seem
better
choic
term
sensit
measur
either
antibodi
type
alon
method
yield
high
specif
elisa
lfia
reach
level
around
elisaand
cliabas
method
perform
better
term
sensit
follow
lfia
fia
sensit
rang
http
wwwncbinlmnihgovpubm
medrxiv
http
medrxivorg
biorxiv
http
wwwbiorxivorg
search
term
use
coronaviru
diseas
igm
igg
antibodi
antibodi
elisa
rapid
test
refer
select
articl
also
search
search
conclud
april
four
differ
research
independ
evalu
search
result
disagr
initi
evalu
resolv
consensu
impos
languag
criteria
includ
studi
written
english
chines
elig
articl
requir
meet
follow
criteria
studi
report
case
confirm
either
nat
rtpcr
sequenc
document
infect
combin
nat
clinic
find
b
result
concern
igm
andor
igg
antibodi
use
varieti
method
consid
elig
studi
report
comparison
case
non
individu
well
case
seri
report
data
patient
data
extract
studi
includ
avail
first
author
last
name
percentag
male
patient
mean
age
patient
mean
number
day
onset
percentag
sever
criticallyil
patient
addit
differ
method
use
determin
igg
igm
also
record
along
detail
order
construct
conting
tabl
obtain
estim
sensit
specif
obtain
number
true
posit
tp
fals
posit
fp
true
neg
tn
fals
neg
fn
studi
report
patient
record
tp
fn
immunoassay
method
use
antibodi
ab
detect
studi
includ
present
metaanalysi
includ
enzymelink
immunosorb
assay
elisa
chemiluminesc
enzym
immunoassay
clia
fluoresc
immunoassay
fia
pointofcar
poc
later
flow
immunoassay
lfia
base
immunochromatographi
method
creat
detect
igg
andor
igm
antibodi
even
total
antibodi
mainli
rbd
andor
n
viral
protein
human
serablood
sampl
elisa
method
variat
includ
captur
principl
igm
indirect
igg
doubl
antigen
sandwich
total
antibodi
detect
elisa
give
quantit
data
antibodi
measur
absorb
valu
cutoff
valu
determin
testplat
lfia
immunochromatographi
base
assay
use
colloid
gold
conjug
antigen
test
rapid
perform
test
strip
nitrocellulos
give
qualit
result
judg
optic
inspect
usual
minut
sampl
applic
lfia
purchas
compani
specif
antigen
lfia
base
report
due
fact
compani
provid
n
base
lfia
assum
unspecifi
case
lfia
n
base
clia
chemiluminesc
base
assay
mainli
develop
compani
give
quantit
result
use
analyz
analyz
batch
random
access
possibl
give
result
within
half
hour
best
case
clia
detect
antin
anti
igg
igm
antibodi
one
studi
detect
antin
assum
n
base
igg
igm
clia
studi
without
relev
inform
fia
denot
fluoresc
immunoassay
perform
multitest
cover
slide
base
fluoresc
immunochromatographi
aiequantum
dotbas
fluoresc
immunochromatograph
assay
afia
latter
rapid
need
analyz
perform
qualiti
assess
includ
studi
use
qualiti
assess
diagnost
accuraci
studi
tool
offer
review
manag
softwar
revman
quada
qualiti
assess
tool
specif
develop
systemat
review
diagnost
accuraci
studi
consist
four
key
domain
patient
select
index
test
refer
standard
flow
time
domain
rate
low
risk
high
risk
unclear
risk
use
bivari
metaanalyt
method
modifi
metaanalysi
diagnost
test
method
shown
equival
socal
hsroc
method
use
logittransform
tpr
true
posit
rate
fpr
fals
posit
rate
order
model
sensit
specif
well
account
betweenstudi
variabl
heterogen
studi
includ
inform
logit
tpr
includ
miss
random
assumpt
order
maxim
sampl
allow
model
betweenstudi
variabl
correl
begg
rank
correl
test
egger
regress
test
use
logit
tpr
evalu
possibl
public
bia
analysi
perform
use
stata
stata
corpor
colleg
station
texa
usa
command
mvmeta
method
moment
multivari
metaanalysi
metaregress
statist
signific
set
p
metaanalysi
perform
case
two
studi
avail
wherea
metaregress
test
public
bia
studi
avail
electron
search
reveal
articl
pubm
medrxiv
biorxiv
identifi
elig
studi
scrutini
figur
includ
total
individu
case
healthi
non
individu
studi
report
data
case
control
studi
report
data
case
studi
use
rtpcr
nucleic
acidbas
test
nat
gold
standard
case
ascertain
wherea
studi
ascertain
case
use
combin
molecular
clinic
featur
summari
inform
includ
studi
present
tabl
consid
result
differ
kit
separ
base
analysi
group
test
base
method
specif
antigen
use
total
identifi
kit
differ
compani
plu
variou
inhous
test
produc
research
purpos
separ
analysi
would
imposs
sever
studi
report
result
multipl
test
individu
howev
includ
metaanalysi
sinc
analyz
test
separ
one
studi
compar
sever
differ
lfia
test
use
result
one
median
perform
even
though
differ
small
studi
report
sampl
multipl
popul
case
consid
distinct
studi
total
report
result
elisabas
test
detect
antin
anti
igg
igm
antibodi
sbase
elisa
gener
perform
better
compar
base
n
antigen
igg
igm
seem
perform
similarli
combin
igg
igm
seem
superior
lead
sensit
ci
method
seem
rather
high
specif
rang
metaregress
analysi
show
mean
number
day
diseas
onset
proport
severecrit
patient
influenc
overal
sensit
igg
test
egger
begg
test
detect
public
bia
small
studi
effect
cliabas
test
use
studi
case
antin
anti
igg
igm
investig
analysi
also
pool
togeth
studi
consid
ns
antigen
studi
use
antigen
sensit
detect
igg
seem
better
compar
igm
vs
combin
igm
igg
yield
slightli
wors
sensit
ci
estim
aris
two
studi
patient
thu
larg
uncertainti
specif
rang
metaregress
analysi
reveal
mean
number
day
diseas
onset
influenc
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
overal
outcom
igg
test
begg
test
provid
evid
public
bia
igg
analysi
studi
report
result
lfiabas
test
major
test
identifi
antibodi
n
antigen
result
obtain
igg
igm
analysi
also
pool
togeth
studi
consid
ns
antigen
studi
use
antigen
igg
igm
seem
perform
compar
rather
low
sinc
sensit
rang
combin
igg
igm
yield
better
estim
still
lower
sensit
compar
elisabas
test
specif
case
rang
largest
overal
analysi
pool
togeth
studi
use
n
ns
antigen
combin
igg
igm
antibodi
yield
sensit
ci
specif
ci
metaregress
analysi
reveal
mean
number
day
diseas
onset
influenc
overal
outcom
igg
iggigm
test
egger
begg
test
could
find
evid
public
bia
small
studi
effect
lastli
fiabas
test
found
three
studi
use
combin
n
antigen
igg
igm
show
similar
sensit
specif
howev
sampl
small
studi
patient
due
small
number
studi
test
public
bia
metaregress
could
appli
nonpharmaceut
intervent
includ
increas
test
rate
contact
trace
school
closur
ban
mass
gather
physic
distanc
restrict
movement
cordon
sanitair
effect
reduc
transmiss
rate
wuhan
china
set
howev
type
intervent
tremend
societ
econom
consequ
potenti
result
social
disorgan
great
recess
one
approach
deescal
public
health
measur
return
state
normalci
maintain
epidemiolog
vigil
abil
respond
fast
viral
resurg
identifi
peopl
immun
estim
proport
entir
popul
approach
would
indic
immun
peopl
includ
healthcar
worker
go
back
work
without
risk
health
other
help
reopen
border
monitor
develop
herd
immun
unfortun
human
immun
respons
new
pathogen
well
studi
yet
serolog
test
recent
develop
employ
differ
method
target
either
igg
igm
attempt
fill
knowledg
gap
systemat
review
summar
evid
studi
involv
individu
metaanalysi
show
method
yield
high
specif
method
elisa
lfia
reach
level
higher
elisaand
cliabas
method
perform
better
term
sensit
follow
lfia
fia
sensit
rang
sampl
qualiti
low
antibodi
concentr
especi
time
test
soon
person
infect
antibodi
develop
yet
late
igm
antibodi
decreas
disappear
could
potenti
explain
low
abil
antibodi
test
identifi
peopl
accord
kinet
measur
includ
studi
igm
peak
day
drop
slowli
igg
reach
peak
concentr
day
igm
antibodi
disappear
metaanalysi
show
metaregress
igg
test
better
sensit
sampl
taken
longer
onset
symptom
corrobor
lower
specif
igm
antibodi
compar
igg
includ
studi
provid
data
stratifi
time
onset
symptom
separ
stratifi
analysi
feasibl
goal
futur
studi
moreov
irrespect
method
combin
iggigm
test
seem
better
choic
term
sensit
measur
either
antibodi
type
alon
analys
also
show
test
use
antigen
sensit
n
antigenbas
test
probabl
due
higher
sensit
earlier
immun
respons
antigen
specif
perhap
due
less
crossreact
less
conserv
region
spike
protein
exist
coronavirus
sarscov
combin
n
antigen
improv
sensit
final
despit
suboptim
sensit
antibodi
test
could
certainli
supplement
nat
diagnosi
peopl
suspect
infect
case
direct
comparison
antibodi
test
nat
also
need
futur
studi
current
review
hand
studi
perform
patient
antibodi
test
accuraci
issu
deserv
attent
assess
instanc
crossreact
human
endem
coronavirus
could
make
antibodi
test
less
specif
produc
fals
posit
result
low
specif
may
import
consequ
term
diagnosi
popul
surveil
individu
level
fals
posit
result
pose
risk
peopl
never
infect
perhap
allow
work
travel
consid
immun
popul
level
regard
epidemiolog
studi
given
low
preval
set
moment
fals
posit
may
inflat
preval
estim
give
distort
pictur
lower
mortal
rate
higher
popul
immun
realiti
hand
low
sensit
may
result
fals
assum
person
infect
consequ
jeopard
measur
prevent
spread
epidem
base
result
metaanalysi
elisa
test
achiev
specif
higher
sensit
could
safer
choic
stage
pandem
clia
test
show
compar
sensit
slightli
decreas
specif
lfia
test
hand
particularli
attract
larg
seropreval
studi
use
poc
test
show
high
specif
compar
elisa
lower
sensit
estim
taken
account
design
perform
seropreval
studi
instanc
adjust
properli
obtain
posit
neg
find
individu
level
perhap
mix
strategi
could
adopt
instanc
retest
neg
find
note
even
test
highli
accur
much
protect
immun
unknown
true
presenc
bind
antibodi
might
mean
peopl
inde
develop
high
titer
neutral
antibodi
thu
immun
reinfect
research
rhesu
macaqu
infect
promis
though
show
reinfect
occur
follow
rechalleng
dose
strain
final
viral
load
declin
rapidli
seroconvers
peopl
may
remain
infecti
despit
truli
posit
antibodi
test
pg
conceiv
studi
particip
data
collect
perform
analysi
pk
gb
nd
gn
particip
data
collect
interpret
result
author
particip
draft
manuscript
author
read
approv
final
version
manuscript
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
igm
n
igg
n
clia
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
tabl
result
metaanalysi
differ
type
antibodi
test
list
characterist
includ
studi
pool
sensit
specif
along
confid
interv
variabl
found
statist
signific
metaregress
result
test
public
bia
descript
test
antibodi
ab
antigen
ag
see
method
section
mdfo
mean
day
onset
sever
percent
patient
sever
critic
condit
na
applic
ab
ag
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
